Date(s) - 18 Apr 2013
11:00 AM - 12:00 PM
April 18, 2013
Time: 2pm ET / 11am PT Register Today!
Hosted by: John Carroll, Editor-in-Chief, FierceCRO
|Over the past few years Big Pharma and a growing number of up-and-coming biotechs alike have focused their attention on developing new drugs for rare diseases. Lured by clearly defined markets and the prospect of commercializing six-figure therapies with small, focused sales forces, rare diseases have become one of the hottest fields in the industry.
Editor-in-Chief John Carroll will host a panel of experts to discuss R&D strategies, patient communications and recruitment, and new regulatory changes which promise to shorten development timelines with an eye to bringing more therapies to market even faster.
|Giles Campion, Chief Medical Officer & Senior VP of R&D, Prosensa
|Dr. Gerry Cox, VP of Clinical Development for Rare Diseases, Genzyme
|Todd Stutzman, Director of Pharmaceutics, Catalent